13575-74-1

Basic information

• Product Name: 4-(3,4-DIMETHOXYPHENYL)BUTYRIC ACID
• Synonyms: 4-(3,4-DIMETHOXYPHENYL)BUTYRIC ACID;LABOTEST-BB LT00452952;Nsc286140;3,4-DiMethoxybenzenebutanoic Acid;4-(3,4-Dimethoxyphenyl)butyric acid 99%
• CAS NO: 13575-74-1
• Molecular Formula: C₁₂H₁₆O₄
• Molecular Weight: 224.25
• Product Categories: C11 to C12;Carbonyl Compounds;Carboxylic Acids;Aromatics;Intermediates
• Mol File: 13575-74-1.mol
• Article Data: 19

Chemical Properties

• Melting Point: 62-63 °C(lit.)
• Boiling Point: 210 °C6 mm Hg(lit.)
• Flash Point: 210°C/6mm
• Appearance: /
• Density: 1.1697 (rough estimate)
• Vapor Pressure: 3.47E-06mmHg at 25°C
• Refractive Index: 1.5130 (estimate)
• PKA: 4.74±0.10(Predicted)
• CAS DataBase Reference: 4-(3,4-DIMETHOXYPHENYL)BUTYRIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(3,4-DIMETHOXYPHENYL)BUTYRIC ACID(13575-74-1)
• EPA Substance Registry System: 4-(3,4-DIMETHOXYPHENYL)BUTYRIC ACID(13575-74-1)

Safety Data

• Hazard Codes: Xi
• Statements: 36
• Safety Statements: 26
• WGK Germany: 3
• Hazardous Substances Data: 13575-74-1(Hazardous Substances Data)

Usage

Uses

Different sources of media describe the Uses of 13575-74-1 differently. You can refer to the following data:
1. 4-(2,3-Dimethoxyphenyl)butanoic acid is a butyrate analogue with effects on apoptosis, proliferation and histone deacetylase (HDAC) activity in HT-29 colorectal cancer cells.
2. 4-(3,4-Dimethoxyphenyl)butyric acid may be used in chemical synthesis studies.

InChI:InChI=1/C12H16O4/c1-15-10-7-6-9(8-11(10)16-2)4-3-5-12(13)14/h6-8H,3-5H2,1-2H3,(H,13,14)

Upstream product

• 5333-34-6 3-(3,4-dimethoxybenzoyl)propionic acid 
• 98799-43-0 trans-4-(3,4-dimethoxyphenyl)but-3-enoic acid 
• 124-38-9 carbon dioxide 
• 3945-85-5 1-bromo-3-(3,4-dimethoxyphenyl)propane 
• 93-15-2 1,2-dimethoxy-4-(2-propenyl)benzene 
• 91-16-7 1,2-dimethoxybenzene 
• 120-14-9 3,4-dimethoxy-benzaldehyde 
• 2316-26-9 3,4-dimethoxycinnamic acid 
• 3929-47-3 3-(3,4-dimethoxyphenyl)-1-propanol 
• 2107-70-2 3,4-methoxycinnamic acid 
• 64-18-6 formic acid 
• 348143-75-9 4-(3,4-dimethoxyphenyl)butanoic acid chloride 
• 93-40-3 (3,4-Dimethoxyphenyl)acetic acid 
• 5703-21-9 3,4-dimethoxyphenylacetaldehyde 

Downstream Products

• 231935-01-6 ethyl 4-(3,4-dimethoxyphenyl)butanoate 
• 56880-86-5 4-(3,4-dimethoxyphenyl)butan-1-ol 
• 56242-82-1 4-(2-chloro-4,5-dimethoxyphenyl)butyric acid 
• 54549-75-6 6,7-dihydroxy-3,4-dihydro-1(2H)-naphthalenone 
• 802985-69-9 4-(2-bromo-4,5-dimethoxy-phenyl)-butyric acid 
• 13575-75-2 6,7-dimethoxy-1-oxo-1,2,3,4-tetrahydronaphthalene 
• 348143-75-9 4-(3,4-dimethoxyphenyl)butanoic acid chloride 
• 1445852-57-2 dimethyl 2-((4-(3,4-dimethoxyphenyl)butanoyl)oxy)succinate 
• 51487-58-2 1,4-bis(3,4-dimethoxyphenyl)butane 
• 98799-68-9 2-(6-Isopropoxy-7-methoxy-1-oxo-1,2,3,4-tetrahydro-naphthalen-2-yl)-3,4,5-trimethoxy-benzoic acid 
• 15462-10-9 2,3,8,9-tetramethoxybenzophenanthridine 
• 15288-01-4 7-hydroxy-6-methoxy-3,4-dihydronaphthalen-1(2H)-one 
• 15288-02-5 6-hydroxy-7-methoxy-1-tetralone 
• 52259-72-0 norfagaronine 

Relevant articles and documents

Identification of First-in-Class Inhibitors of Kallikrein-Related Peptidase 6 That Promote Oligodendrocyte Differentiation

Multiple sclerosis (MS) is an autoimmune demyelinating disease of the central nervous system (CNS) that causes severe motor, sensory, and cognitive impairments. Kallikrein-related peptidase (KLK)6 is the most abundant serine protease secreted in the CNS, mainly by oligodendrocytes, the myelin-producing cells of the CNS, and KLK6 is assumed to be a robust biomarker of MS, since it is highly increased in the cerebrospinal fluid (CSF) of MS patients. Here, we report the design and biological evaluation of KLK6's low-molecular-weight inhibitors, para-aminobenzyl derivatives. Interestingly, selected hit compounds were selective of the KLK6 proteolytic network encompassing KLK1 and plasmin that also participate in the development of MS physiopathology. Moreover, hits were found noncytotoxic on primary cultures of murine neurons and oligodendrocyte precursor cells (OPCs). Among them, two compounds (32 and 42) were shown to promote the differentiation of OPCs into mature oligodendrocytes in vitro constituting thus emerging leads for the development of regenerative therapies.

-

-

Highly enantioselective [3+2] coupling of cyclic enamides with quinone monoimines promoted by a chiral phosphoric acid

Enantioselective [3+2] coupling of cyclic enamides with quinone monoimines was realised using a chiral phosphoric acid as a catalyst. This transformation allowed for the synthesis of highly enantioenriched polycyclic 2,3-dihydrobenzofurans (up to 99.9% ee). The absolute configuration of one product was determined by an X-ray crystal structural analysis. We also found a possible mechanism for this reaction.